

CONTENTS

ENVIRONMENTAL HEALTH CRITERIA FOR NEUROTOXICITY RISK ASSESSMENT FOR HUMAN HEALTH: PRINCIPLES AND APPROACHES

PREAMBLE	ix
ACRONYMS AND ABBREVIATIONS	xix
1. SUMMARY AND RECOMMENDATIONS	1
1.1 Summary	1
1.2 Recommendations	4
2. INTRODUCTION	7
2.1 Purpose of the publication	7
2.2 General principles of neurotoxicity risk assessment	9
2.3 Examples of chemical-induced neurotoxicity	10
2.4 Definitions and critical concepts in neurotoxicology	17
2.4.1 Neurotoxicity versus adverse effects	17
2.4.2 Direct versus indirect effects	18
2.4.3 Primary versus secondary effects	18
2.4.4 Transient versus persistent effects	19
2.4.5 Compensation	19
2.5 Assumptions in neurotoxicity risk assessment	20
2.6 Criteria for quality of data used in risk assessment	21
2.6.1 Sensitivity	22
2.6.2 Specificity	22
2.6.3 Reliability/validity	23
2.6.4 Dose-response	23
3. BASIC PRINCIPLES FOR NEUROTOXICITY RISK ASSESSMENT	25
3.1 Neurobiological principles	25
3.1.1 Structure of the nervous system	25
3.1.2 Transport processes	28
3.1.3 Ion channels	29

3.1.4	Neurotransmission	30
3.1.5	Metabolism	32
3.1.6	Blood-brain and blood-nerve barriers	32
3.1.7	Regenerative ability	35
3.1.8	Neuroendocrine system	37
3.1.9	Integrative function of the nervous system	38
3.2	Toxicological principles	38
3.2.1	Neurotoxicity	38
3.2.2	Structure-activity relationships	39
3.3	Susceptible populations	40
3.3.1	Developing nervous system	41
3.3.2	Aged nervous system	43
3.3.3	Genetic susceptibility	44
3.4	Types of effects on the nervous system	44
3.4.1	Neurotransmitter function	45
3.4.2	Morphological effects	45
3.4.3	Behaviour	46
3.5	Summary	47

4. HUMAN NEUROTOXICITY 49

4.1	Introduction	49
4.2	Methods for assessing human neurotoxicity	51
4.2.1	Clinical neurological evaluation	51
4.2.2	Neuropsychological and neurobehavioural testing	52
4.2.2.1	Individual neuropsychological assessment	52
4.2.2.2	Cognitive testing batteries	55
4.2.2.3	Psychiatric and symptom questionnaires	61
4.2.2.4	Behavioural neurophysiological tests	62
4.2.3	Electrophysiological tests	65
4.2.4	Neuroimaging techniques	69
4.3	Types of human studies	70
4.3.1	Clinical case-studies	70
4.3.2	Epidemiological studies	71
4.3.2.1	Assessment of exposure and dose	75
4.3.2.2	Causal inferences and confounding factors	82

Deutsche
Zentralbibliothek
für Medizin
Köln

38 M

000 ZB-38 41564

4.3.3	Human experimental exposure studies	85
4.3.4	Developmental human neurotoxicity studies	87
4.4	Ethical considerations in human studies	89
4.5	Summary	90
5.	ANIMAL NEUROTOXICITY	92
5.1	Animal models	92
5.1.1	Role of animal models	92
5.1.2	Special considerations in animal models	93
5.1.2.1	Dosing scenario	93
5.1.2.2	Species differences	94
5.1.2.3	Other factors	95
5.1.2.4	Statistical considerations	96
5.1.2.5	Animal welfare issues	97
5.2	End-points of neurotoxicity	98
5.2.1	Introduction	98
5.2.2	Behavioural end-points	98
5.2.2.1	Observational batteries	101
5.2.2.2	Motor activity	104
5.2.2.3	Neuromotor function	106
5.2.2.4	Sensory function	107
5.2.2.5	Learning and memory	108
5.2.2.6	Attention	110
5.2.2.7	Schedule-controlled behaviour	111
5.2.2.8	Pharmacological challenges	113
5.2.3	Neurophysiological end-points	114
5.2.3.1	Peripheral nerve function studies	116
5.2.3.2	Sensory evoked potentials	117
5.2.3.3	Electroencephalography	119
5.2.3.4	Seizure activity	119
5.2.3.5	Electromyography	120
5.2.3.6	Spinal reflex excitability	120
5.2.3.7	Ion channel function and synaptic transmission	121
5.2.3.8	Hippocampal field potentials	121
5.2.4	Neurochemical end-points	122
5.2.4.1	General biochemical measures	123
5.2.4.2	Cholinesterase-inhibiting compounds	124
5.2.4.3	Cellular protein markers	125

5.2.5	Neuroendocrine end-points	126
5.2.6	Structural end-points	127
5.2.7	Axonal transport	135
5.3	Special issues in developmental neurotoxicity	137
5.4	<i>In vitro</i> methods	141
5.5	Testing strategies for neurotoxicity	144
5.6	Emerging issues	146
5.6.1	Genetic approaches to neurotoxicology	146
5.6.2	Neuroimmunotoxicology	147
5.6.3	Endocrine dysfunction/disruption	148
5.7	Summary	148
6.	NEUROTOXICITY RISK ASSESSMENT	150
6.1	Introduction	150
6.2	Hazard identification	150
6.2.1	Human studies	151
6.2.2	Animal studies	151
6.2.3	Special issues	152
6.2.3.1	Animal-to-human extrapolation	152
6.2.3.2	Susceptible populations	152
6.2.3.3	Cumulative toxicity	152
6.2.3.4	Recovery of function	153
6.2.4	Characterization of the database and classification schemes	154
6.3	Dose-response assessment	160
6.4	Exposure assessment	166
6.5	Risk characterization	167
6.5.1	Introduction	167
6.5.2	Integration	168
6.5.3	Quality of the database	169
6.5.4	Descriptors of neurotoxicity risk	170
6.5.4.1	Estimation of the number of individuals	170
6.5.4.2	Presentation of specific scenarios	170
6.5.4.3	Risk characterization for highly exposed individuals	170
6.5.4.4	Risk characterization for highly sensitive or susceptible individuals	171
6.5.4.5	Other risk descriptors	172

6.6 Summary	173
REFERENCES	174
RESUME ET RECOMMANDATIONS	211
RESUMEN Y RECOMENDACIONES	218